AIM recently underwent testing by third-party labs required by the FDA for 510(k) filing.
AIM passed the biocompatibility testing, and the gas flow test results came back better than expected, making AIM a strong contender for the NORA (Non-Operating Room Anesthesia) patient population. The startup is in the process of filing for FDA clearance.